GoPro Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? GoPro Inc trades at $1.19 (market cap $243.50M), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.32 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is far larger — about 9.3× GoPro Inc's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| GPRO | SLS | |
|---|---|---|
Market Cap | $243.50M | $2.27B |
Volume | 11,527,160 | 4,179,659 |
Sector | Technology | Health |
52-Week High | $2.35 | $15.46 |
52-Week Low | $0.58 | $1.39 |
Typical Hold Time | 45 Days | — |
Enterprise Value | $302.28M | $2.14B |
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $1.22, down 7.58% on the day, amid volatile trading following a recent surge driven by merger news and influencer investment. The stock shows bullish technical signals with oversold RSI conditions, but fundamentals remain weak with declining revenues and persistent net losses. Recent developments include a proposed $285 million merger with Starman Optical and significant stake acquisition by YouTube creator Markiplier, creating both opportunity and uncertainty for shareholders.
The outlook remains highly speculative with the merger offering potential upside but facing shareholder litigation over valuation concerns. Key risks include continued operational losses, competitive pressures from smartphones, and merger execution challenges. Analyst sentiment is mixed with only 21% buy ratings, reflecting skepticism about the company's standalone prospects versus merger-driven speculation.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →